Valsartan (Diovan) Recall: Cancer-Causing Contamination
Valsartan (Diovan) is prescribed for high blood pressure and heart failure. It is a generic medication manufactured and distributed by many different multinational pharmaceutical giants including Teva Pharmaceuticals, Alembic Pharmaceuticals, Novartis, Camber Pharmaceuticals and Novel Laboratories among others.
On July 13, 2018 the FDA began recalling Valsartan manufactured by Chinese manufacturer Zhejang Huahai Pharmaceuticals and distributed by pharmaceutical giants Teva Pharmaceuticals, Major® Pharmaceuticals and Solco Healthcare. Since July 13, 2018 the recall has been expanded two more times: on August 10, 2018 to include Valsartan manufactured by Zhejang Huahai Pharmaceuticals and distributed by Camber Pharmaceuticals and again on August 22, 2018 to include Valsartan manufactured by Zhejang Huahai Pharmaceuticals Torrent Pharmaceuticals. The specific Valsartan manufactured by Zhejang Huahai have been contaminated with a chemical, N-nitrosodimethylamine (NDMA), a known carcinogen.
The specific Valsartan being recalled has been linked to liver damage (fibrosis, scarring, abnormal liver function tests) along with kidney and liver tumors – both malignant and benign. The longer one used the contaminated Valsartan, the more likely the user is to develop these catastrophic injuries.
Not all Valsartan has been recalled so it is important that you DO NOT DISCONTINUE VALSARTAN USE WITHOUT SPEAKING TO YOUR PRESCRIBER FIRST.
Loncar Associates is evaluating cases for products liability litigation for anyone who used Valsartan since January 1, 2012. Loncar Associates has not pursued claims involving generic manufacturers since the landmark Pliva, Inc. v. Mensing decision by the United States Supreme Court back in 2011. That astonishing decision provided immunity from civil liability to most generic pharmaceutical manufacturers regarding product warning labels. Valsartan is likely an exception to that Supreme Court ruling as these cases involve manufacturing defects that lead to contaminated products, not labeling defects.
Loncar Associates is currently investigating cases involving:
- Intestinal tract cancers – colon/ colorectal
- Kidney cancer, kidney tumors (benign)
- Stomach cancer
- Liver cancer, liver tumors (benign), liver injuries
- Bladder cancers
If you or a loved one developed digestive tract, liver, pancreatic or kidney problems anytime since January 1, 2012, contact the law firm of Loncar Associates immediately. The law places time limits in which litigation must be initiated, called statutes of limitations and repose. Failure to timely file your lawsuit can and likely will result in your justice being denied. These time limits can deny you compensation even if you are not aware that you have a case.
Since 1999, Loncar Associates has been at the forefront of pharmaceutical and medical device litigation nationwide. Our clients have obtained successful verdicts for their injuries. Don’t wait until it is too late. Contact the law offices of Loncar Associates immediately for a free, no-obligation evaluation of your potential case.
Don’t be a victim twice. The justice-makers at Loncar Associates are standing by to discuss your case and your legal options. Call or complete the contact form immediately to discuss your case with an experienced member of our legal team.